A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: No pharmacologic therapy has conclusively proved to be effective for the treatment of nonalcoholic steatohepatitis, which is characterized by insulin resistance, steatosis, and necroinflammation with or without centrilobular fibrosis. Pioglitazone is a thiazolidinedione that ameliorates insulin resistance and improves glucose and lipid metabolism in type 2 diabetes mellitus. METHODS: We randomly assigned 55 patients with impaired glucose tolerance or type 2 diabetes and liver biopsy-confirmed nonalcoholic steatohepatitis to 6 months of treatment with a hypocaloric diet (a reduction of 500 kcal per day in relation to the calculated daily intake required to maintain body weight) plus pioglitazone (45 mg daily) or a hypocaloric diet plus placebo. Before and after treatment, we assessed hepatic histologic features, hepatic fat content by means of magnetic resonance spectroscopy, and glucose turnover during an oral glucose tolerance test ([14C]glucose given with the oral glucose load and [3H]glucose given by intravenous infusion). RESULTS: Diet plus pioglitazone, as compared with diet plus placebo, improved glycemic control and glucose tolerance (P<0.001), normalized liver aminotransferase levels as it decreased plasma aspartate aminotransferase levels (by 40% vs. 21%, P=0.04), decreased alanine aminotransferase levels (by 58% vs. 34%, P<0.001), decreased hepatic fat content (by 54% vs. 0%, P<0.001), and increased hepatic insulin sensitivity (by 48% vs. 14%, P=0.008). Administration of pioglitazone, as compared with placebo, was associated with improvement in histologic findings with regard to steatosis (P=0.003), ballooning necrosis (P=0.02), and inflammation (P=0.008). Subjects in the pioglitazone group had a greater reduction in necroinflammation (85% vs. 38%, P=0.001), but the reduction in fibrosis did not differ significantly from that in the placebo group (P=0.08). Fatigue and mild lower-extremity edema developed in one subject who received pioglitazone; no other adverse events were observed. CONCLUSIONS: In this proof-of-concept study, the administration of pioglitazone led to metabolic and histologic improvement in subjects with nonalcoholic steatohepatitis. Larger controlled trials of longer duration are warranted to assess the long-term clinical benefit of pioglitazone. (ClinicalTrials.gov number, NCT00227110 [ClinicalTrials.gov] .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Significant improvements were observed in hepatic steatosis, hepatocellular ballooning, necrosis, and inflammation; however, fibrosis reduction did not reach statistical significance compared with placebo.”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [202]
In the citing paper
“Accruing randomized clinical trial data suggest that pioglitazone, GLP-1 RA, and a dual GIP and GLP-1 RA have potential benefits in terms of decreasing hepatic steatosis and in the resolution of MASH without worsening of fibrosis in individuals with biopsy-proven MASH or those at higher risk of clinically significant liver fibrosis identified with noninvasive tests (146-153).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [146]
In the citing paper
“Treatment with exenatide reduced liver steatosis [109,146,150] and when added to pioglitazone, an oral hypoglycemic and insulin sensitizing drug approved for the treatment of T2D that acts on nuclear peroxisome proliferator activated receptor-gamma (PPAR-γ) [147], potentiated the known action of pioglitazone in reducing hepatic fat [92].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [92]
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Self-citationYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298
Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,296
Research works printed but not linked: 3
- 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
- 10.1210/jc.87.6.2784 · doi:10.1210/jc.87.6.2784 · Paper page
- 10.1172/JCI22422 · DOI · Paper page
Cited by
Items 401–500 of 1,003
Said, A., & Akhter, A. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.0284 · Cited by 111
Kashyap, S. R., Diab, D. L., Baker, A. R., Yerian, L., Bajaj, H., Gray‐McGuire, C., Schauer, P. R., Gupta, M., Feldstein, A. E., Hazen, S. L., et al. (2009) · Obesity · doi:10.1038/oby.2009.89 · Cited by 110
“Various drug treatments for T2DM, hypertension, and hyperlipidemia with thiazolidinediones, statins, ace inhibitors, biguanide, and insulin therapy have been shown to improve clinical severity of MS (2,30) and may alter adipokine levels measured in this cohort and thus blurred the distinction between histological grou…”
BackgroundMethodTreating NASH by targeting peroxisome proliferator-activated receptors
Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 108
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
Ali, R., & Cusi, K. (2009) · Annals of Medicine · doi:10.1080/07853890802552437 · Cited by 110
Self-citationNonalcoholic Fatty Liver Disease: A Review of the Spectrum of Disease, Diagnosis, and Therapy
Kopec, K. L., & Burns, D. L. (2011) · Nutrition in Clinical Practice · doi:10.1177/0884533611419668 · Cited by 135
Wei, Q., Xu, X., Guo, L., Li, J., & Li, L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.635556 · Cited by 126
“Although the insulin sensitizer pioglitazone can play a antihyperglycemic role and improve liver function, it is used cautiously in clinical practice because of its problematic safety in long-term use and side effects such as weight gain and edema (7).”
BackgroundHayashizaki, Y., Kurosaki, E., Takasu, T., Mitori, H., Yamazaki, S., Koide, K., & Takakura, S. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.009 · Cited by 112
Review: Treatment options for nonalcoholic fatty liver disease
Lam, B., & Younossi, Z. M. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09359964 · Cited by 108
“…features of NASH are less uniform [Argo et al. 2009; Chalasani et al. 2009; Juurlink et al. 2009; Aithal et al. 2008; Lutchman et al. 2007; Belfort et al. 2006; Ratziu et al. 2006, 2008; Promrat et al. 2004; Sanyal et al. 2004; Neuschwander-Tetri et al. 2003; Shadid and Jensen, 2003;…”
BackgroundInfluentialMancini, M., Prinster, A., Annuzzi, G., Liuzzi, R., Giacco, R., Medagli, C., Cremone, M., Clemente, G., Maurea, S., Riccardi, G., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.05.032 · Cited by 117
“Spectroscopically determined fat fraction is equivalent to tissue triglyceride concentration, and several clinical trials [42-44] on NAFLD have used spectroscopic magnetic resonance as an outcome measure.”
BackgroundPrevention of Diabetes With Pioglitazone in ACT NOW
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., et al. (2013) · Diabetes · doi:10.2337/db13-0265 · Cited by 109
“PGZ reduces plasma free fatty acid (FFA) levels, mobilizes fat out of muscle (21) and liver (22), and redistributes fat from visceral to subcutaneous depots (12,16).”
BackgroundSelf-citationNonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 107
Ectopic fat and insulin resistance
Lettner, A., & Roden, M. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0032-z · Cited by 106
Zisser, A., Ipsen, D. H., & Tveden-Nyborg, P. (2021) · Biomedicines · doi:10.3390/biomedicines9040365 · Cited by 104
Alqahtani, S. A., & Schattenberg, J. M. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s295524 · Cited by 129
“studies did not explicitly study the effect of thiazolidinediones on elderly cohorts.(145,146) Given that thiazolidine-”
BackgroundPardo, V., González‐Rodríguez, Á., Muntané, J., Kozma, S. C., & Valverde, Á. M. (2015) · Food and Chemical Toxicology · doi:10.1016/j.fct.2015.03.029 · Cited by 113
Cusi, K., Kashyap, S., Gastaldelli, A., Bajaj, M., & Cersosimo, E. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00624.2006 · Cited by 105
“, phosphoenolpyruvate carboxykinase [PEPCK] and glyceraldehyde-3-phosphate dehydrogenase [GPDH]) as well as FFA uptake and reesterification (6), increasing plasma adiponectin levels [which were low and unchanged by acipimox treatment in this cohort of insulinresistant FH subjects (data not shown)] (5), and improving F…”
BackgroundSelf-citationNonalcoholic fatty liver disease – current status and future directions
Demir, M., Lang, S., & Steffen, H. (2015) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12291 · Cited by 105
Non-alcoholic fatty liver disease: a practical approach to treatment
Dyson, J. K., Anstee, Q. M., & McPherson, S. (2014) · Frontline Gastroenterology · doi:10.1136/flgastro-2013-100404 · Cited by 105
Adipose tissue as a linchpin of organismal ageing
Nguyen, T., & Corvera, S. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01046-3 · Cited by 127
“Systemically, TZDs decrease hepatic and peripheral triglyceride accumulation 180 , decrease visceral adiposity 181 and increase circulating adiponectin 179,182 —reversing age-related adipose tissue dysfunction.”
Bell, L. N., Wang, J., Muralidharan, S., Chalasani, S., Fullenkamp, A. M., Wilson, L. A., Sanyal, A. J., Kowdley, K. V., Neuschwander-Tetri, B. A., Brunt, E. M., et al. (2012) · Hepatology · doi:10.1002/hep.25805 · Cited by 104
Mouse models of inherited lipodystrophy
Savage, D. B. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.002907 · Cited by 105
The role of ChREBP in carbohydrate sensing and NAFLD development
Régnier, M., Carbinatti, T., Parlati, L., Benhamed, F., & Postic, C. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00809-4 · Cited by 101
Lee, Y.-H., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E.-J., Cho, Y. M., & Lee, B.-W. (2017) · Journal of Korean Medical Science · doi:10.3346/jkms.2017.32.1.60 · Cited by 104
“Several clinical studies have investigated the effects of antidiabetic TZDs on NAFLD (21-25).”
BackgroundResultMiller, D. M., McCauley, K. F., & Dunham‐Snary, K. J. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70132 · Cited by 153
“Insulin sensitizers, such as pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, have shown promise in improving liver histology and reducing fibrosis [211].”
Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis
Vercruysse, P., Sinniger, J., El Oussini, H., Scekic-Zahirovic, J., Dieterlé, S., Dengler, R., Meyer, T., Zierz, S., Kassubek, J., Fischer, W., et al. (2016) · Brain · doi:10.1093/brain/aww004 · Cited by 104
Cariello, M., Piccinin, E., & Moschetta, A. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.012 · Cited by 120
Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials
Mannucci, E., Monami, M., Lamanna, C., Gensini, G. F., & Marchionni, N. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00892.x · Cited by 103
Socha, P., Horvath, A., Vajro, P., Dziechciarz, P., Dhawan, A., & Szajewska, H. (2009) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31818e04d1 · Cited by 103
“Pioglitazone, which did not show any effect on transaminase normalization, reduced necrosis and inflammation with no effect on steatosis in 1 large study (24); similar effects were observed in another small study (33).”
BackgroundMethodInfluentialZarrinpar, A., & Loomba, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12084 · Cited by 103
“addition to metabolic improvements, treatment with pioglitazone was associated with reductions in hepatic fat content and corresponding improvements in histological findings.(111) Although an early meta-analysis of rando-”
Non-alcoholic fatty liver disease and cardiovascular risk
Brea, Á., & Puzo, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.085 · Cited by 123
“Their use has produced varied results [136–138].”
Chronic Liver Disease in the Hispanic Population of the United States
Carrion, A. F., Ghanta, R., Carrasquillo, O., & Martin, P. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.04.027 · Cited by 102
Pintó, X., Fanlo-Maresma, M., Corbella, E., Corbella, X., Mitjavila, M. T., Moreno, J. J., Casas, R., Estruch, R., Corella, D., Bulló, M., et al. (2019) · The Journal of Nutrition · doi:10.1093/jn/nxz147 · Cited by 101
“Most patients with NAFLD have excess body weight, and current therapies are limited to weight reduction by diet and exercise (6) and treatment with insulin sensitizers (7).”
BackgroundGastaldelli, A., Sabatini, S., Carli, F., Gaggini, M., Bril, F., Belfort‐DeAguiar, R., Positano, V., Barb, D., Kadiyala, S., Harrison, S., et al. (2021) · Liver International · doi:10.1111/liv.15005 · Cited by 101
Self-citationRoeb, E., Canbay, A. E., Tacke, F., Bantel, H., Bojunga, J., de Laffolie, J., Demir, M., Denzer, U. W., Geier, A., Hofmann, W. P., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2283 · Cited by 126
Current therapeutic strategies in non‐alcoholic fatty liver disease
Dowman, J. K., Armstrong, M. J., Tomlinson, J. W., & Newsome, P. N. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01403.x · Cited by 100
Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes
Verspohl, E. J. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.003319 · Cited by 112
Reversibility of liver fibrosis
Ramachandran, P., & Iredale, J. P. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31740-5 · Cited by 98
Yoneda, M., Honda, Y., Ogawa, Y., Kessoku, T., Kobayashi, T., Imajo, K., Ozaki, A., Nogami, A., Taguri, M., Yamanaka, T., et al. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001990 · Cited by 99
Bril, F., Portillo Sanchez, P., Lomonaco, R., Orsak, B., Hecht, J., Tio, F., & Cusi, K. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00867 · Cited by 97
“For instance, in our prior RCT of pioglitazone vs placebo in patients with NASH (43), plasma ALT and AST”
MethodAnti-fibrotic therapy: Lost in translation?
Schuppan, D., & Pinzani, M. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60008-7 · Cited by 102
Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.004 · Cited by 96
Self-citationThe Multifaceted Roles of Macrophages in NAFLD Pathogenesis
Vonderlin, J., Chavakis, T., Sieweke, M., & Tacke, F. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.03.002 · Cited by 96
Fatty liver as a consequence and cause of insulin resistance: Lessons from type 2 diabetic liver
Takamura, T., Misu, H., Ota, T., & Kaneko, S. (2012) · Endocrine Journal · doi:10.1507/endocrj.ej12-0228 · Cited by 96
Review article: the use of potentially hepatotoxic drugs in patients with liver disease
GUPTA, N. K., & LEWIS, J. H. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03822.x · Cited by 96
Yan, H., Xia, M., Chang, X., Xu, Q., Bian, H., Zeng, M., Rao, S., Yao, X., Tu, Y., Jia, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024895 · Cited by 95
Thibaut, R., Gage, M. C., Pineda‐Torra, I., Chabrier, G., Venteclef, N., & Alzaid, F. (2022) · The FEBS Journal · doi:10.1111/febs.15877 · Cited by 95
Nonalcoholic fatty liver disease: from pathogenesis to patient care
Perlemuter, G., Bigorgne, A., Cassard, A., & Naveau, S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0505 · Cited by 108
“A very recent, placebo-controlled trial reported in 2006 that 6 months of treatment with pioglitazone improved patients' aminotransferase levels, steatosis, necrosis and inflammation, but not fibrosis”
BackgroundRecent advances in nonalcholic fatty liver disease
Greenfield, V., Cheung, O., & Sanyal, A. J. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282fbccf2 · Cited by 94
Nonalcoholic fatty liver disease: new treatments
Hardy, T., Anstee, Q. M., & Day, C. P. (2015) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000175 · Cited by 89
A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA
Cazanave, S. C., Mott, J. L., Elmi, N. A., Bronk, S. F., Masuoka, H. C., Charlton, M. R., & Gores, G. J. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014654 · Cited by 93
Evaluation and management of obesity-related nonalcoholic fatty liver disease
Nugent, C., & Younossi, Z. M. (2007) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0879 · Cited by 101
Majzoub, A. M., Nayfeh, T., Barnard, A., Munaganuru, N., Dave, S., Singh, S., Murad, M. H., & Loomba, R. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16583 · Cited by 92
Younossi, Z. M., Reyes, M. J., Mishra, A., Mehta, R., & Henry, L. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12543 · Cited by 94
“On the other hand, the PIVENS trial randomly assigned 247 nondiabetic patients with NASH to one of three groups: pioglitazone, vitamin E or placebo group.(29) Liver biopsy results were assessed”
MethodRecent research trends and updates on nonalcoholic fatty liver disease
Yoo, J., Kim, W. K., Kim, M. Y., Jun, D. W., Kim, S. G., Yeon, J.-E., Lee, J. W., Cho, Y. K., Park, S. H., & Sohn, J. H. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.0037 · Cited by 97
Mitochondrial Dysfunction in the Transition from NASH to HCC
Léveillé, M., & Estall, J. L. (2019) · Metabolites · doi:10.3390/metabo9100233 · Cited by 100
Barb, D., Kalavalapalli, S., Leiva, E. G., Bril, F., Huot-Marchand, P., Dzen, L., Rosenberg, J. T., Junien, J., Broqua, P., Rocha, A. O., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.045 · Cited by 116
Self-citationFarglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
McHutchison, J. G., Goodman, Z. D., Patel, K., Makhlouf, H. R., Rodriguez‐Torres, M., Shiffman, M. L., Rockey, D. C., Husa, P., Chuang, W., Levine, R. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.003 · Cited by 91
Erion, D. M., Park, H., & Lee, H. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.3.268 · Cited by 101
“AST concentrations, as well as, reduce hepatic fat concentrations by 54% (45).”
BackgroundEdwards, C., & Cusi, K. J. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.06.007 · Cited by 123
Self-citationA review of non‐alcoholic fatty liver disease in non‐obese and lean individuals
Ahadi, M., Molooghi, K., Masoudifar, N., Namdar, A. B., Vossoughinia, H., & Farzanehfar, M. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15353 · Cited by 107
Insulin Resistance Markers in Children
Eyzaguirre, F. C., & Verónica Mericq, G. (2009) · Hormone Research in Paediatrics · doi:10.1159/000183894 · Cited by 98
Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 97
Seko, Y., Sumida, Y., Tanaka, S., Mori, K., Taketani, H., Ishiba, H., Hara, T., Okajima, A., Umemura, A., Nishikawa, T., et al. (2017) · Hepatology Research · doi:10.1111/hepr.12837 · Cited by 89
Glass, O., Filozof, C., Noureddin, M., Berner-Hansen, M., Schabel, E., Omokaro, S. O., Schattenberg, J. M., Barradas, K., Miller, V., Francque, S., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.030 · Cited by 89
Chen, A., Tang, Y., Davis, V., Hsu, F.-F., Kennedy, S. M., Song, H., Turk, J., Brunt, E. M., Newberry, E. P., & Davidson, N. O. (2013) · Hepatology · doi:10.1002/hep.26318 · Cited by 87
Eliasson, B., Möller-Goede, D. L., Eeg‐Olofsson, K., Wilson, C., Cederholm, J., Fleck, P. R., Diamant, M., Taskinen, M., & Smith, U. (2012) · Diabetologia · doi:10.1007/s00125-011-2447-3 · Cited by 95
Drug-induced liver disease in 2006
Arundel, C., & Lewis, J. H. (2007) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3280b17dfb · Cited by 99
Balas, B., Belfort, R., Harrison, S. A., Darland, C., Finch, J., Schenker, S., Gastaldelli, A., & Cusi, K. J. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2007.04.013 · Cited by 93
“While an increase in body weight in an already obese population is undesirable, it has been shown to be associated with an overall decrease in systemic inflammation, an improvement in adipose tissue insulin resistance and glucose metabolism [7].”
BackgroundMethodInfluentialSelf-citationKhattab, M. A., Emad, M., Abdelaleem, A., Eslam, M., Atef, R., Shaker, Y., & Hamdy, L. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02171.x · Cited by 92
Targher, G., Marchesini, G., & Byrne, C. D. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.04.002 · Cited by 98
Athyros, V. G., Pοlyzos, S. A., Kountouras, J., Katsiki, N., Anagnostis, P. G., Doumas, M. N., & Mantzoros, C. S. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190405164313 · Cited by 93
Pydyn, N., Miękus, K., Jura, J., & Kotlinowski, J. (2020) · Pharmacological Reports · doi:10.1007/s43440-019-00020-1 · Cited by 97
Non-alcoholic Fatty Liver Disease in Children
Manco, M., Bottazzo, G. F., Vito, R. D., Marcellini, M., Mingrone, G., & Nobili, V. (2008) · touchREVIEWS in Endocrinology · doi:10.1080/07315724.2008.10719744 · Cited by 87
Zhang, F., Kong, D., Lu, Y., & Zheng, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1046-x · Cited by 92
Hirata, T., Tomita, K., Kawai, T., Yokoyama, H., Shimada, A., Kikuchi, M., Hirose, H., Ebinuma, H., Irie, J., Ojiro, K., et al. (2013) · International Journal of Endocrinology · doi:10.1155/2013/587140 · Cited by 97
“In studies using several strains of animal models, telmisartan inhibited fat deposition, inflammation, and fibrosis in the liver [20, 29–31].”
BackgroundRole of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis
Lomonaco, R., Ortiz-Lopez, C., Orsak, B., Finch, J., Webb, A., Bril, F., Louden, C., Tio, F., & Cusi, K. (2011) · Hepatology · doi:10.1002/hep.24483 · Cited by 86
“82 for fibrosis).(13) Only 7% of patients had a biopsy length less than 1 centimeter, which is within the 14% reported by other groups.”
BackgroundMethodInfluentialSelf-citationDiabetes medications and risk of HCC
Plaz Torres, M. C., Jaffe, A., Perry, R., Marabotto, E., Strazzabosco, M., & Giannini, E. G. (2022) · Hepatology · doi:10.1002/hep.32439 · Cited by 86
Kudo, H., Yata, Y., Takahara, T., Kawai, K., Nakayama, Y., Kanayama, M., Oya, T., Morita, S., Sasahara, M., Mann, D. A., et al. (2009) · Liver International · doi:10.1111/j.1478-3231.2009.02006.x · Cited by 86
“Although treatment with pioglitazone, a PPARg agonist, led to clear metabolic and histological improvements in subjects with NASH, it did not significantly reduce fibrosis as compared with a placebo plus dietary intervention (8).”
BackgroundInsulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status
Stein, L. L., Dong, M. H., & Loomba, R. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0072-z · Cited by 84
Alqahtani, S. A., & Schattenberg, J. M. (2021) · Dove Medical Press (Taylor and Francis Group) · Cited by 85
Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., Nevola, R., Marfella, R., & Sasso, F. C. (2023) · Biomedicines · doi:10.3390/biomedicines11020468 · Cited by 102
“In the PIVENS (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis) study, vitamin E (800 mg/day) was superior to a placebo in NASH histology improvement in adults without diabetes and cirrhosis [77,78].”
BackgroundDella Pepa, G., Russo, M., Vitale, M., Carli, F., Vetrani, C., Masulli, M., Riccardi, G., Vaccaro, O., Gastaldelli, A., Rivellese, A. A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108984 · Cited by 84
Self-citationCorey, K. E., Klebanoff, M. J., Tramontano, A. C., Chung, R. T., & Hur, C. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4044-2 · Cited by 84
“It has been shown to lead to histological improvements in patients with NASH and diabetes [14].”
BackgroundCurrent treatment of non‐alcoholic fatty liver disease
Ahmed, M. H., & Byrne, C. D. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00926.x · Cited by 84
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Francque, S., & Vonghia, L. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00898-6 · Cited by 84
“Glitazones have been approved for the treatment of diabetes but were also shown to be effective in improving histological lesions of NASH in several trials [37, 44, 45].”
BackgroundRole of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD
Fuchs, C. D., Claudel, T., & Trauner, M. (2014) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2014.08.001 · Cited by 91
PPARγ is essential for protection against nonalcoholic steatohepatitis
Wu, C. W., Chu, E. S., Lam, C. N. Y., Cheng, A. S. L., Lee, C., Wong, V. W., Sung, J. J. �., & Yu, J. Q. (2010) · Gene Therapy · doi:10.1038/gt.2010.41 · Cited by 90
Malik, R., Chang, M., Bhaskar, K. R., Nasser, I. A., Curry, M. P., Schuppan, D., Byrnes, V., & Afdhal, N. H. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05731.x · Cited by 87
Lipoprotein metabolism in nonalcoholic fatty liver disease
Jiang, Z. G., Simon, K. A., & Zemin, Y. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20120077 · Cited by 103
Villareal, D. T., Koster, J. C., Robertson, H., Akrouh, A., Miyake, K., Bell, G. I., Patterson, B. W., Nichols, C. G., & Polonsky, K. S. (2009) · Diabetes · doi:10.2337/db09-0025 · Cited by 82
Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study
Cui, J., Chen, C., Lo, M., Schork, N., Bettencourt, R., Gonzalez, M. P., Bhatt, A., Hooker, J., Shaffer, K., Nelson, K. E., et al. (2016) · Hepatology · doi:10.1002/hep.28674 · Cited by 82
“Vitamin E and thiazolidinediones have been shown to improve hepatic steatosis in NAFLD patients.((38-40)) However, few treatments have been shown to be effective in reversing NAFLD-associated hepatic fibrosis.”
BackgroundPerspectives on Treatment for Nonalcoholic Steatohepatitis
Lassailly, G., Caiazzo, R. J., Pattou, F. N., & Mathurin, P. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.004 · Cited by 94
Karsdal, M. A., Henriksen, K., Nielsen, M. J., Byrjalsen, I., Leeming, D. J., Gardner, S., Goodman, Z., Patel, K., Krag, A., Christiansen, C., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00283.2016 · Cited by 82
Management of NAFLD in primary care settings
Wong, V. W. S., Zelber‐Sagi, S., Cusi, K., Carrieri, P., Wright, E., Crespo, J., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15404 · Cited by 81
Self-citationGlycogen synthase kinase-3 (GSK-3) inhibition attenuates hepatocyte lipoapoptosis
Ibrahim, S. H., Akazawa, Y., Cazanave, S. C., Bronk, S. F., Elmi, N. A., Werneburg, N. W., Billadeau, D. D., & Gores, G. J. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.039 · Cited by 81
“The concentrations of PA used in the experiments varied between 400–800 lM and were similar to the fasting total FFA plasma concentrations observed in human with non-alcoholic steatohepatitis [4,34].”
MethodPPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients
Lange, N. F., Graf, V., Caussy, C., & Dufour, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084305 · Cited by 96
“Given these findings and the concerns regarding cardiovascular adverse effects, rosiglita-zone’s role in the treatment of NASH is currently limited.”
Kantartzis, K., Machicao, F., Machann, J., Schick, F., Fritsche, A., Häring, H.-U., & Stefan, N. (2009) · Clinical Science · doi:10.1042/cs20080306 · Cited by 81
Review article: the reversibility of cirrhosis
Sohrabpour, A. A., Mohamadnejad, M., & Malekzadeh, R. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12044 · Cited by 80
Ganji, S. H., Kukes, G. D., Lambrecht, N., Kashyap, M. L., & Kamanna, V. S. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00181.2013 · Cited by 79
George, J., & Liddle, C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp700110z · Cited by 81
Metadata
- Authors
- Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., Berria, R., Ma, J. Z., Dwivedi, S., Havranek, R., Fincke, C., DeFronzo, R., Bannayan, G. A., Schenker, S., & Cusi, K.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Brooke Army Medical Center (US)
- South Texas Veterans Health Care System (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-11-30
- Volume
- 355
- Issue
- 22
- Pages
- 2297-2307
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103156933
- Cited by
- 1,827
- References
- 38
- Citations by year
- 2026: 44 · 2025: 73 · 2024: 83 · 2023: 78 · 2022: 84 · 2021: 93 · 2020: 73 · 2019: 74 · 2018: 70 · 2017: 93 · 2016: 98 · 2015: 106 · 2014: 92 · 2013: 87 · 2012: 85
- FWCI
- 91.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- National Center for Research Resources (M01RR01346, M01RR001346)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- alcoholic steatohepatitis, thiazolidinediones, insulin resistance, hypocaloric diet, hepatic steatosis, hepatic insulin sensitivity, necroinflammation, liver fibrosis, glucose tolerance, type 2 diabetes, impaired glucose tolerance, hepatic aminotransferases, drug safety, adverse effects
- MeSH terms
- Pioglitazone, Blood Glucose, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Fatty Liver, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Liver, Liver Cirrhosis, Male, Middle Aged, Necrosis, Glucose Intolerance, Caloric Restriction, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.